Literature DB >> 30587700

Value of Placental Growth Factor as a Predictor of Adverse Events During the Acute Phase of Acute Decompensated Heart Failure.

Yasuki Nakada1, Rika Kawakami1, Masaru Matsui1, Tomoya Ueda1, Tomoya Nakano1, Hitoshi Nakagawa1, Taku Nishida1, Kenji Onoue1, Tsunenari Soeda1, Satoshi Okayama1, Makoto Watanabe1, Hiroyuki Okura1, Yoshihiko Saito1.   

Abstract

BACKGROUND: Few biomarkers, even B-type natriuretic peptide (BNP), can predict the long-term outcome in patients with acute decompensated heart failure (ADHF) on the first day of admission. Placental growth factor (PlGF), a member of the vascular endothelial growth factor family of cytokines, is a key molecule in cardiorenal syndrome and a predictor of adverse events in chronic kidney disease patients. However, its significance in ADHF patients remains poorly understood. Methods and 
Results: We studied 408 ADHF patients admitted between April 2011 and December 2016 by measuring their PlGF levels on the first day of admission. Primary endpoints were all-cause and cardiovascular (CV) death. Patients were divided into 2 groups according to PlGF quartiles. Kaplan-Meier analysis revealed that the high PlGF group (quartile 4: ≥12.6 pg/mL) had a worse prognosis than the low PlGF group (quartiles 1-3; <12.6 pg/mL) in terms of all-cause (hazard ratio [HR], 1.56; 95% confidence interval [CI], 1.13-2.14; P<0.01) and CV death (HR, 1.68; 95% CI, 1.04-2.66; P<0.05). After adjustment for covariates, PlGF remained an independent predictor of all-cause and CV death.
CONCLUSIONS: PlGF on the first day of admission was significantly associated with both all-cause and CV death, suggesting that it provides novel prognostic information in the acute phase of ADHF.

Entities:  

Keywords:  Acute decompensated heart failure; Biomarkers; Outcomes; Placental growth factor

Mesh:

Substances:

Year:  2018        PMID: 30587700     DOI: 10.1253/circj.CJ-18-0523

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  3 in total

Review 1.  Cardiorenal Syndrome: New Pathways and Novel Biomarkers.

Authors:  Guido Gembillo; Luca Visconti; Maria Ausilia Giusti; Rossella Siligato; Alessia Gallo; Domenico Santoro; Alessandro Mattina
Journal:  Biomolecules       Date:  2021-10-26

2.  Serum syndecan-1 concentration in hospitalized patients with heart failure may predict readmission-free survival.

Authors:  Yuichiro Kitagawa; Itta Kawamura; Keiko Suzuki; Hideshi Okada; Takuma Ishihara; Hiroyuki Tomita; Kodai Suzuki; Chihiro Takada; So Sampei; Soichiro Kano; Kohei Kondo; Hirotaka Asano; Yugo Wakayama; Ryo Kamidani; Yuki Kawasaki; Hirotsugu Fukuda; Ayane Nishio; Takahito Miyake; Tetsuya Fukuta; Ryu Yasuda; Hideaki Oiwa; Yoshinori Kakino; Nagisa Miyazaki; Takatomo Watanabe; Takahiro Yoshida; Tomoaki Doi; Akio Suzuki; Shozo Yoshida; Hitoshi Matsuo; Shinji Ogura
Journal:  PLoS One       Date:  2021-12-08       Impact factor: 3.240

3.  Impact of Chronic Kidney Disease on the Associations of Cardiovascular Biomarkers With Adverse Outcomes in Patients With Suspected or Known Coronary Artery Disease: The EXCEED-J Study.

Authors:  Hiromichi Wada; Tsuyoshi Shinozaki; Masahiro Suzuki; Satoru Sakagami; Yoichi Ajiro; Junichi Funada; Morihiro Matsuda; Masatoshi Shimizu; Takashi Takenaka; Yukiko Morita; Kazuya Yonezawa; Hiromi Matsubara; Yujiro Ono; Toshihiro Nakamura; Kazuteru Fujimoto; Akiyo Ninomiya; Toru Kato; Takashi Unoki; Daisuke Takagi; Kyohma Wada; Miyaka Wada; Moritake Iguchi; Hajime Yamakage; Toru Kusakabe; Akihiro Yasoda; Akira Shimatsu; Kazuhiko Kotani; Noriko Satoh-Asahara; Mitsuru Abe; Masaharu Akao; Koji Hasegawa
Journal:  J Am Heart Assoc       Date:  2022-01-20       Impact factor: 6.106

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.